Fundraising Fox
Ascidian Therapeutics
Founded 2020 · 48 employees on LinkedIn · 3 known investors
Find your way into Ascidian Therapeutics
Sign up to see every warm intro you have to Ascidian Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ascidian Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ascidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.
Investors · 3
Also in the syndicate · 1
Apple Tree Partnerslead
Funding
SEC filings, press & company announcements$40M disclosed across 1 of 2 rounds · 2022–2023
- $40MSeries A ExtensionNov 2023 · 4 sources
Apple Tree Partners (lead), Apple Tree Partners (ATP)
Source ↗ - Undisclosed amountSeries AOct 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 2
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Ascidian Therapeutics.
In the news
Frequently asked questions
- What does Ascidian Therapeutics do?
- Ascidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.
- Who are Ascidian Therapeutics's investors?
- Ascidian Therapeutics's investors include ATP, Scion Life Sciences.
- How much funding has Ascidian Therapeutics raised?
- Ascidian Therapeutics has disclosed $40M raised across 1 of its 2 known rounds.